Evidence map›Paper›PMID 40768197›Full record

ArticleClinical nuclear medicine2026

Evaluation of Rare Insulin-derived Amyloidoma With 18 F-FDG PET/CT.

Fathima Fijula Palot Manzil, Joshua Eichhorn, Pokhraj Suthar

Abstract readCase Reports
In one paragraph

Article in Clinical nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Fathima Fijula Palot ManzilDepartment of Diagnostic Radiology and Nuclear Medicine, Rush University Medical Center, Chicago, IL.
Joshua EichhornDepartment of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR.
Pokhraj SutharDepartment of Diagnostic Radiology and Nuclear Medicine, Rush University Medical Center, Chicago, IL.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyloidosis causes extracellular tissue deposition of insoluble polymeric protein fibrils. Insulin-derived amyloidosis (AIns) is a rare complication of insulin therapy, causing insulin accumulation at the repeated injection site, forming subcutaneous lumps. This causes impaired insulin absorption, affecting further glycemic management. Our patient had anterior abdominal soft tissue lesions and a biopsy concerning multiple myeloma. 18 F-FDG PET/CT done to evaluate any osseous/other extraosseous lesions demonstrated hypermetabolic lesions confined to the anterior abdomen. The mass was excised, and histopathology revealed insulin-derived amyloidoma. Per the literature search, only 1 previous case of AIns has been evaluated with PET/CT. PET/CT helps assess disease extent, localize, guide biopsy, and follow-up.

Indexed as

AmyloidosisFluorodeoxyglucose F18InsulinPositron Emission Tomography Computed TomographyHumansMaleMiddle AgedFluorodeoxyglucose F18InsulinCongo red staininsulin-derived amyloidosis

Identifiers

PMID40768197
PMCPMC13132038

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.